Business
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University Sc...
About this update from Omega Pacific Resources, Inc.
[{"type":"text","content":"\n \n \n \n Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n - Collaboration to Leverage Omega Epigenomic Controllers™, a New Class of mRNA Therapeutics as Programmable Epigenetic Medicines, for Ocular Diseases by Targeting and Controlling Specific Ocular Disease Genes\n \n \n PR Newswire\n \n \n \n \n \n CAMBRIDGE, Mass.\n \n ,\n \n Oct. 14, 2021\n \n /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (\"Omega\"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the\n \n Stanford University\n \n School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.\n \n \n Under the terms of the collaboration, Omega and members of the Ophthalmology Department of\n \n Stanford University\n \n School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential future OEC development candidates.\n \n Albert Wu\n \n , M.D., Ph.D., FACS, Associate Professor of Ophthalmology, will serve as principal investigator. Other contributors will include\n \n Jeffrey Goldberg\n \n , M.D., Ph.D., Professor and Chair of Ophthalmology, and\n \n Michael Kapiloff\n \n , M.D., Ph.D., Associate Professor (Research) of Ophthalmology.\n \n \n \"Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets,\" said\n \n Mahesh Karande\n \n , President and Chief Executive Officer of Omega Therapeutics. \"We will continue exploration of the broad potential of our disruptive platform and OECs, our new class of mRNA therapeutics as programmable epige...